SynthesisBMC nephrology2026
Comparison of genetic profile and kidney outcomes between very early-onset and non-very-early-onset autosomal dominant polycystic kidney disease in children: a systematic review and meta-analysis.
Synthesis in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and a leading cause of kidney failure. Although typically considered an adult-onset condition, a subset of patients present in utero or within the first 18 months of life (very early-onset ADPKD; VEO-ADPKD). This subgroup may experience a more severe disease course.
methodsA systematic search of MEDLINE was conducted to identify studies reporting clinical, genetic, radiologic and kidney outcome data in children (< 18 years) with VEO-ADPKD. Case series including fewer than three VEO-ADPKD patients were excluded. ADPKD diagnosis was based on 2019 international consensus radiologic criteria, including age-appropriate cystic and/or enlarged kidneys, with supportive family history and/or genetic confirmation. Children with non-VEO-ADPKD reported within the same studies were included for comparison. Outcomes of interest included inheritance patterns, genetic profile, hypertension, proteinuria, chronic kidney disease (CKD), kidney failure, and perinatal death. Descriptive analyses and Bayesian model-averaged random-effects meta-analyses were performed using JASP (version 0.9.13) with a conditional model specification. A non-informative Beta (1,1) prior was used.
resultsNineteen studies comprising 736 ADPKD children (VEO: 335, non-VEO: 401) met inclusion criteria. Bayesian model-averaged meta-analysis (8 studies) showed higher odds in VEO-ADPKD for hypertension (OR 2.08, 95% CrI 1.00-2.70; BF₁₀ 18.2), proteinuria (OR 1.58, 1.00-2.60; BF₁₀ 4.0), CKD (OR 1.77, 1.00-2.66; BF₁₀ 7.4) and kidney failure (OR 1.99, 1.00-2.69; BF₁₀ 10.6). Evidence for maternal inheritance in VEO-ADPKD was weak (OR 1.31, 1.00-2.44; BF₁₀ 1.6). Biallelic PKD1 mutations (38/158 vs. 0/147) and perinatal death (34/320 vs. 0/401) occurred exclusively in the VEO group and are reported descriptively, as complete separation precluded pooled estimation.
conclusionVEO-ADPKD represents a distinct, high-risk pediatric phenotype characterized by earlier and more severe kidney involvement. These findings emphasize the importance of early diagnosis, comprehensive genetic evaluation, and close monitoring. Genetic testing is essential to identify children with biallelic mutations, representing a clinical entity more akin to mild autosomal recessive polycystic kidney disease. Standardized phenotyping and prospective pediatric studies are needed to guide early therapeutic interventions and improve long-term outcomes in this rare population. CLINICAL TRIAL NUMBER: NA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.